

1 **A Case-Report on Double Seronegative**
2 **Neuromyelitis Optica Spectrum Disorder (DN**
3 **NMOSD)**

4
5
6
7

8
9 **ABSTRACT**

10 Neuromyelitis optica spectrum disorder, formerly known as neuromyelitis optica or Devic's disease, affects roughly 0.3 to 4.4 individuals per 100,000. NMOSD is a peculiar inflammatory disease of the central nervous system that manifests clinically as optic neuritis, transverse myelitis, and specific brainstem and brain-inside syndrome. Here we presented a 55-year-old patient who had been normal months prior to developing numbness of the right half of the face and a history of swaying to the right side. He initially received treatment elsewhere with a five-day course of methylprednisolone pulse therapy, resulting in symptom improvement. However, three months later, he experienced a recurrence and came for further management after receiving a second pulse of steroids. The investigations revealed left-sided facial nerve involvement, sensory loss, and impaired joint position sense and vibration sense in the toes, positive Romberg's sign, and gait ataxia. The magnetic resonance imaging showed T2/FLAIR hyperintense lesions, and cerebrospinal fluid analysis supported a possible diagnosis of neuromyelitis optica spectrum disorder. However, the absence of serum Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein antibodies complicates the diagnosis. The patient was treated effectively for the condition with appropriate glycemic control and is under monitoring for recurrence and progression for any modifications in the treatment as needed. This case highlights the complexity of diagnosing the disease, especially in the context of negative antibody tests, and underscores the need for careful differentiation from other central nervous system disorders.

11 **Keywords:** *Double seronegative; Neuromyelitis Optica Spectrum Disorder; Optic neuritis; Transverse myelitis; Aquaporin*
12 *4 antibody; Intravenous Immunoglobulin.*

13
14
15
16 **1. INTRODUCTION**

17
18 A rare inflammatory condition of the central nervous system (CNS), called neuromyelitis optica spectrum disorder (NMOSD),
19 which was previously thought to be a subtype of multiple sclerosis (MS), is now a widely acknowledged distinct disease
20 entity.[1] NMOSD, formerly known as Neuromyelitis optica or Devic's illness, was initially identified by Dr. Eugene Devic in
21 1894 while evaluating a patient presented with optic neuritis with neuromuscular manifestations.[2] Roughly 0.3 to 4.4
22 people per 100,000 were impacted by NMOSD. This condition is typically seen more in women (80%) and is most common
23 among patients aged 30 to 40.[3] The clinical manifestations of NMOSD are optic neuritis, myelitis, and specific brainstem
24 and brain inside syndromes.[4] Presence of pathogenic immunoglobulin G (IgG) antibodies to aquaporin-4 (AQP4), a
25 common CNS water channel, and Myoglobin Oligodendrocyte Glycoprotein (MOG) antibodies are linked to NMOSD.
26 Irrespective of ethnicity, there is a significant female preponderance among patients with AQP4-IgG-seropositive status,
27 who constitute a significant proportion of NMOSD, whereas the female:male ratio may vary from 10:1, whereas among
28 seronegative patients, this might reach 3:1.[5] Double-negative NMOSD is a condition in which NMOSD is negative for both
29 aquaporin-4 antibody (AQP4-IgG) and myelin oligodendrocyte glycoprotein antibodies (MOG-IgG). In recent studies, the
30 median onset age of DN NMO/NMOSD ranged from 32 to 43 years with almost equal sex ratios or with a mild female
31 predominance in contrast with the marked female predominance observed in AQP4-IgG+ patients.[6] Most individuals
32 identified as having DN NMOSD will have a combination of brain or brainstem instances typical of NMOSD, longitudinally

extensive ON, and (or) longitudinally extensive transverse myelitis (LETM). The inflammatory response gets more intense in DN NMOSD, as reflected by significantly increased serum proinflammatory cytokines, similar to that in AQP4-IgG+ NMOSD. Several studies have proven that the CSF of DN NMO/NMOSD patients contains a substantial quantity of interleukin 6 (IL-6).[7] Combining strategies may yield further understanding because DN NMOSD is a miscellaneous group without a biomarker. It has been set up that DN NMOSD cases express four distinct patterns: classic NMO-suchlike (high chance of bilateral ON and LETM with normal brain appearance); spinal MS-suchlike (had short-member myelitis and no MS-suchlike brain lesions); NMO- suchlike with brain involvement (a history of NMOSD-brain lesions and LETM); and MS-like (frequently had cortical lesions and central tone signs).[8] Double-seronegative cases exhibited more extended subependymal lesions than Myelin Oligodendrocyte Glycoprotein Antibody-associated Diseases (MOGAD) cases and added extended corpus callosum lesions than MOGAD and AQP4-IgG NMOSD cases. It showed more extended lesions of the optic pathways, with additional parts being affected, particularly in the intracranial regions, and also experienced worse residual disability compared with those with AQP4-IgG NMOSD.[9] Patients experiencing central nervous system (CNS) inflammatory conditions, such as multiple sclerosis or sarcoidosis, may mimic the symptoms of double-negative neuromyelitis optica spectrum disorder (DN NMOSD), which can manifest as either monophasic or relapsing. It is important to note that DN NMOSD cannot be diagnosed based on a single complaint or symptom; rather, it represents a pattern of symptoms that requires careful consideration for different treatment approaches.[10]

2. PRESENTATION OF CASE

A 55-year-old male patient who is a known diabetic, was apparently normal months back developed numbness of right half of face and history of swaying to the right side. Patient got outside pulse dose of methyl prednisolone for 5 days and on tapering dose of steroids and patient symptoms improved over a period of time. Patient developed decreased sensation in left half of face and swaying to the left with history of blurring of vision after three months and got 2nd pulse dose intravenous steroids and on tapering oral steroids. Now patient came for further management.

2.1 NEUROLOGICAL EXAMINATION:

- Extra Ocular Movement (EOM): Full, indicating no restriction in eye movements.
- Bilateral Pupillary Equal and Reactive to Light (B/L PERL): Change of 3mm, which is within normal limits.
- No relative afferent pupillary defect (RAPD).
- Fundus (both eyes): Disc margins are visualized bilaterally. Facial sensation reduced in the left half of the face. This suggests a possible lesion affecting the sensory pathways for the left side of the face, likely involving the trigeminal nerve or central pathways.
- Deviation of angle of mouth to right side, possibly due to facial nerve involvement.
- Reduced nasolabial fold on left side. Not able to hold air tightly in mouth due to weakness in the orbicularis oris muscle on the left side.
- Wrinkling present in left forehead and able to close left eye tightly: This suggests that the upper facial muscles are still functioning, indicating that the facial nerve might not be completely affected.
- Motor Examination:
 - Tone is normal in all limbs.
 - Power is 5/5 in both upper limbs, 4-/5 in proximal lower limbs, and 5/5 in distal lower limbs.
 - Deep tendon reflexes (DTR) are likely normal.
- Sensory Examination
 - Touch and pain sensations are intact, but joint position sense (JPS) and vibration sense are impaired in the toes bilaterally, indicating possible peripheral neuropathy or spinal cord involvement.
- Romberg's Test Positive: This indicates a problem with proprioception or vestibular function.
- Cerebellar Examination:
 - Finger-nose test (FNT) and fast finger-nose test (FFNT) are intact.
 - Heel-knee test (HKT) is impaired, suggesting some cerebellar dysfunction.
 - No truncal ataxia, but gait ataxia and broad-based gait are present, indicating possible cerebellar or vestibular issues.
 - Impaired tandem walking further supports this.
- Spine & Cranium Normal: Indicates no structural abnormalities detected. No Signs of Meningeal Irritation.

Further diagnostic imaging (like MRI) and tests may be warranted to determine the underlying cause. Here's a detailed analysis:

(i) Cerebrospinal fluid Analysis:

- CSF glucose level: 152 mg/dl.

- 89 - Protein - 0.1 mg/dl is quite low.
90 - The presence of occasional RBCs.
91 - ELISA: Serum NMO (AQP) and MOG not detected.
92 - In the follow-up CSF analysis, the protein level increased to 73.40 mg/dl, which is elevated and suggests a possible
93 inflammatory process. The cell count of 10 cells/cu.mm with a differential count showing 30% neutrophils and 70%
94 lymphocytes.
95 - CSF Oligoclonal Bands Immunoglobulin test (CSF OCB-IgG) – absent.
96

97 **(ii) MRI Findings:**

- 98 - The MRI findings of T2/FLAIR hyperintensity in the right medulla, pons, cerebellar peduncles, and peritrigonal region
99 are suggestive of demyelination. The lack of diffusion restriction or significant contrast enhancement may indicate that the
100 lesions are not acutely inflamed.
101 - The whole spine screening showing no features of demyelination.
102 - Cerebrovascular Doppler is normal. (To assess the flow in the cerebral blood vessels and to evaluate any vascular
103 changes or abnormalities associated with NMOSD).
104

105 **(iii) EDSS (Expanded Disability Status Scale) Score: 2.** (Minimal disability with mild issues in walking and coordination.
106 Patient can walk without assistance, vision is normal with no cognitive impairment).

107
108 **(iv) Chest X-ray:** No significant abnormalities detected.

109
110 **(v) Other Laboratory Findings:**

- 111 - Based on the provided laboratory results, here are the significant findings:

112
113 **Liver Function Test (LFT):**

- 114 - Total Bilirubin (TB): 0.5 mg/dL (normal)
115 - Direct Bilirubin (DB): 0.2 mg/dL (normal)
116 - Alanine Aminotransferase (ALT): 10 U/L (normal, but on the lower side)
117 - Aspartate Aminotransferase (AST): 14 U/L (normal)
118 - Alkaline Phosphatase (ALP): 83 U/L (normal)
119 - Total Protein (TP): 6.3 g/dL (normal)
120 - Albumin (ALB): 3.3 g/dL (normal)
121

122 **Renal Function Test (RFT):**

- 123 - Urea: 29 mg/dL (elevated, normal range is typically 7-20 mg/dL)
124 - Creatinine: 0.8 mg/dL (normal)
125 - Sodium: 140 mmol/L (normal)
126 - Potassium: 4.2 mmol/L (normal)
127

128 **Complete Blood Count (CBC):**

- 129 - Hemoglobin (Hb): 14.5 g/dL (normal)
130 - White Blood Cell Count (WBC): 10,500 cells/microL (slightly elevated, normal range is 4,000-10,000)
131 - Differential Count (DC): Neutrophils: 84%, Lymphocytes: 12%, Monocytes: 3% (high neutrophils may indicate infection
132 or inflammation)
133 - Platelets: 2.54 lakh cells/microL (normal)
134 - Red Blood Cell Count (RBC): 3.99 million cells/microL (normal)
135 - Packed Cell Volume (PCV): 41.8% (normal)
136 - Mean Corpuscular Volume (MCV): 87.8 fL (normal)
137 - Mean Corpuscular Hemoglobin Concentration (MCHC): 34.7 g/dL (normal)
138 - Intravenous Intracranial Pressure Head (IVICH): 30.5 (not typically reported in standard CBC)
139

140 **Glucose Levels:**

- 141 - Random Blood Sugar (RBS): 441 mg/dL (elevated)
142 - Fasting Blood Sugar (FBS): 216 mg/dL (elevated, normal is below 100)
143 - Postprandial Blood Sugar (PPBS): 344 mg/dL (elevated)
144

145 **Significant Results:**

- 146 - Elevated Urea (29 mg/dL) may indicate renal impairment or dehydration.
147 - Elevated WBC (10,500) with high neutrophils (84%) suggests possible infection or inflammation.
148 - Elevated blood sugar levels (RBS 441, FBS 216, PPBS 344) indicate possible diabetes or poor glycaemic control.
149

150 Based on the MRI findings, the presence of T2/FLAIR hyperintensities in the posterior aspect of the right medulla and
151 pons, as well as the right middle and inferior cerebellar peduncle and right peritrigonal region, suggests a demyelinating
152 process. The absence of diffusion restriction and significant contrast enhancement further supports the likelihood of
153 demyelination without acute inflammatory activity. The MRI findings are consistent with NMOSD, particularly given the
154 clinical symptoms and the response to steroid treatment. The lack of demyelination in the whole spine screening also
155 suggests that the process may be localized to the brainstem and cerebellar regions, which is often seen in NMOSD
156 cases.
157

158 In conclusion, the combination of clinical presentation, MRI findings, and response to treatment strongly suggests a
159 diagnosis of NMOSD. Further testing, such as AQP4 antibody testing, would be beneficial to confirm the diagnosis and
160 guide treatment options.
161

162 2.2. CLINICAL COURSE:

163

164 Based on the course of treatment in the hospital, the patient is being managed for a central demyelinating disorder,
165 specifically suspected DN NMOSD. The treatment regimen includes:

- 166 • Intravenous Immunoglobulin (IVIg): Administered at a dose of 2g/kg over 5 days. IVIg to modulate the immune
167 response and reduce inflammation.
- 168 • The patient is on a tapering dose of prednisolone 5mg.
- 169 • Oral Hypoglycaemic Agents (OHAs) and Human Insulin for managing blood glucose levels.
170

171 2.3. ADVICE ON DISCHARGE:

172

- 173 1. Steroids: T.Prednisolone 5mg (3-0-0). To help manage inflammation and symptoms related to the
174 demyelinating disorder.
- 175 2. T.Calcium 150mg (0-2-0), to support bone health, especially important when on long-term steroid therapy.
- 176 3. Oral Hypoglycaemic Agents:
 - 177 • T. Metformin 500mg: To be taken twice a day (1-0-1).
 - 178 • T. Vildagliptin 50mg: To be taken once daily (1-0-0).
 - 179 • T. Glimepride 2mg: To be taken once daily (1-0-0).
 - 180 • T. Voglibose 0.2mg: To be taken once a day (0-0-1).

181 These medications helps to control blood sugar spikes.

- 182 4. Insulin:
 - 183 • INJ Regular insulin: Dosage of 14-12-10 to be administered half an hour before meals for immediate
184 control of blood sugar levels.
 - 185 • INJ. Monotard insulin: Dosage of 14-0-12 to be administered half an hour after meals. This is a long-
186 acting insulin to provide baseline blood sugar control.

187 Additionally, the patient is advised to review in the Neuromedicine department on alternative days after 14 days to monitor
188 progress and adjust treatment as necessary.
189

190 **Challenges in diagnosis:** Since the diagnosis of NMOSD is mostly based on the presence of AQPO4 and/or MOG
191 antibody, as approximately 80% of NMOSD patients can be seropositive, the double seronegative assessment along with
192 optic neuritis was a great challenge. The clinical findings are suggestive of NMOSD with AQPO4 and MOG antibody
193 seronegative.
194

195 3. DISCUSSION

196

197 NMOSD is an autoimmune condition that primarily affects the central nervous system, with a particular affinity for the optic
198 nerves, spinal cord, and brainstem. The autoimmune response is centered around IgG antibodies targeting aquaporin-4.
199 AQP4-IgG antibodies are present in approximately 80% of NMOSD patients. Among those who are negative for AQP4-IgG,
200 about half are classified as having myelin oligodendrocyte glycoprotein (MOG)-antibody positive NMOSD. The

characteristics of double-negative NMOSD still require further clarification. The patient met the diagnostic criteria for "NMOSD with unknown AQP4-IgG," as indicated by the presence of two key clinical features: optic neuritis and acute myelitis. [11]

Epidemiology: The incidence and prevalence of NMOSD vary between 0.05–0.40 and 0.52–4.4 per 100,000 individuals, respectively. Prevalence rates were highest in the French West Indies and South Korea, and lowest in Cuba and Australia. In all regions, the rates were higher in females than in males. [12]

Clinical findings: While NMOSD may manifest as monophasic in AQP4-IgG-negative patients, it usually follows a recurrent course in the majority of AQP4-IgG-positive patients. Patients suspected of having myelitis should be assessed for sensory, motor (including respiratory), bladder/bowel, and sexual dysfunction. Additionally, a wide range of brainstem symptoms beyond APS, such as oculomotor disturbances, facial palsy or numbness, and ataxia, has been observed in NMOSD patients, so comprehensive evaluation for brainstem involvement is essential. Even after a single attack, patients may experience significant, lasting disability, particularly if the attack is not promptly and appropriately treated.[13]

Biomarkers: Double seronegative (DN) NMOSD is not a single disease but a syndrome with varying treatment needs. In AQP4-IgG-negative NMOSD cases, the percentage of DN patients varies from 0% to 79%. Like AQP4-IgG-positive NMOSD, DN NMOSD shows an increased inflammatory response, with elevated serum pro-inflammatory cytokines. Studies have found high levels of interleukin 6 (IL-6) in the CSF of DN patients, and CSF neurofilament light chain (NFL) levels are notably higher in DN NMOSD compared to AQP4-IgG-positive NMOSD or MOGAD, suggesting significant neuronal damage. Most DN NMOSD patients experience longitudinally extensive optic neuritis, transverse myelitis, and/or typical brainstem attacks. Approximately 20-50% of these patients suffer from severe visual impairment.[14]

Diagnostic techniques: Due to its heterogeneity and absence of a unique biomarker, DN NMOSD requires a combination of diagnostic techniques. In this case, the patient's clinical findings suggest left-sided facial nerve involvement, potentially from a central lesion affecting the facial nerve pathway, such as a stroke. Sensory loss and impaired JPS/vibration sense in the toes may indicate peripheral neuropathy or CNS involvement. A positive Romberg's test and gait ataxia could point to vestibular or cerebellar issues. Differential count shows lymphocytic predominance. OCB, AQP4, and MOG are negative. MRI reveals T2/FLAIR hyperintense lesions in the right peritrigonal region. All these findings suggest a demyelinating process, possibly DN NMOSD.

Treatment: Treatment for DN NMOSD is based on approaches used for antibody-positive NMOSD and includes glucocorticoids, azathioprine, mycophenolate mofetil, rituximab, methotrexate, and mitoxantrone. A study showed an 86% reduction in relapse rate with tacrolimus. Some DN NMOSD patients may also respond to anti-IL-6R drugs or IV immunoglobulin.[15],[16],[17]

4. CONCLUSION

In conclusion, we presented a rare case of DN NMOSD, a condition that remains challenging to diagnose and treat. It is uncertain whether DN NMOSD is primarily an astrocytopathylike AQP4-positive NMOSD. Diagnosis relies on clinical features, MRI, and antibody testing. Currently, no specific treatments are approved for relapse prevention in DN NMOSD, and it is managed similarly to seropositive NMOSD. If left untreated, the disease can lead to severe disability, including visual impairment and wheelchair dependence. Prompt diagnosis and empirical treatment are essential for better outcomes and improved quality of life for DN NMOSD patients.

CONSENT

The participation was on a voluntary basis and written informed consent was obtained from the individual who participated in the case report.

251 **ETHICAL APPROVAL**

252
253 As per international standards or university standards written ethical approval has been collected and preserved by the
254 author.

255 **DISCLAIMER (ARTIFICIAL INTELLIGENCE)**

257 OPTION 1:

258 AUTHOR(S) HEREBY DECLARE THAT NO GENERATIVE AI TECHNOLOGIES SUCH AS LARGE
259 LANGUAGE MODELS (CHATGPT, COPILOT, ETC.) AND TEXT-TO-IMAGE GENERATORS HAVE BEEN
260 USED DURING THE WRITING OR EDITING OF THIS MANUSCRIPT.

261 OPTION 2:

262 AUTHOR(S) HEREBY DECLARE THAT GENERATIVE AI TECHNOLOGIES SUCH AS LARGE LANGUAGE
263 MODELS, ETC. HAVE BEEN USED DURING THE WRITING OR EDITING OF MANUSCRIPTS. THIS
264 EXPLANATION WILL INCLUDE THE NAME, VERSION, MODEL, AND SOURCE OF THE GENERATIVE AI
265 TECHNOLOGY AND AS WELL AS ALL INPUT PROMPTS PROVIDED TO THE GENERATIVE AI
266 TECHNOLOGY

267 DETAILS OF THE AI USAGE ARE GIVEN BELOW:

268 1.

269 2.

270 3.

271 S

272 **REFERENCES**

- 273
274 1. Siriratnam P, Huda S, Butzkueven H, Van Der Walt A, Jokubaitis V, Monif M. A comprehensive review of the advances
275 in neuromyelitis optica spectrum disorder. *Autoimmunity Reviews* [Internet]. 2023 Oct 16;22(12):103465. Available from:
276 <https://doi.org/10.1016/j.autrev.2023.103465>
- 277 2. Shumway CL, Patel BC, Tripathy K, De Jesus O. Neuromyelitis Optica Spectrum Disorder (NMOSD) [Internet].
278 StatPearls - NCBI Bookshelf. 2024. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK572108/>
- 279 3. humway, C. L., Patel, B. C., Tripathy, K., & De Jesus, O. (2024, January 8). Neuromyelitis Optica Spectrum Disorder
280 (NMOSD). StatPearls - NCBI Bookshelf.
- 281 4. Hor, J. Y., Asgari, N., Nakashima, I., Broadley, S. A., Leite, M. I., Kissani, N., Jacob, A., Marignier, R., Weinschenker, B.
282 G., Paul, F., Pittock, S. J., Palace, J., Wingerchuk, D. M., Behne, J. M., Yeaman, M. R., & Fujihara, K. (2020). Epidemiology
283 of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. *Frontiers in Neurology*, 11.
- 284 5. V. Papp, M. Magyari, O. Aktas, T. Berger, S.A. Broadley, P. Cabre, *et al.* Worldwide incidence and prevalence of
285 neuromyelitis optica: a systematic review. *Neurology.*, 96 (2) (2021), pp. 59-77.
- 286 6. Jarius S, Aktas O, Azyzenberg I, Bellmann-Strobl J, Berthele A, Giglhuber K, et al. Update on the diagnosis and treatment
287 of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group
288 (NEMOS). Part I: Diagnosis and differential diagnosis. *Journal of Neurology*. 2023 Apr 6;270(7):3341–68.
- 289 7. Thauxenet E, Du Iris De Terdanak L, Mariotto S, et al. Compared CSF biomarker profile of AQP4-Ab, MOG-Ab and
290 double seronegative NMOSD reveals specificities with potential therapeutic implications. *Wilt Selekt*
291 2019; 25 (SunRh 2): 724-725. [Google Scholar]
- 292 8. Wu Y, Geraldine R, Juryńczyk M, Palace J. Double-negative neuromyelitis optica spectrum disorder. *Multiple Sclerosis*
293 *Journal* [Internet]. 2023 Sep 23;29(11–12):1353–62. Available from: <https://doi.org/10.1177/13524585231199819>
- 294 9. Fragoso DC, De Paula Salles LMO, Pereira SLA, Callegaro D, Sato DK, De Medeiros Rimkus C. AQP4-IgG NMOSD,
295 MOGAD, and double-seronegative NMOSD: is it possible to depict the antibody subtype using magnetic resonance
296 imaging? *Arquivos De Neuro-Psiquiatria* [Internet]. 2023 Jun 1;81(06):533–43. Available from: [https://doi.org/10.1055/s-](https://doi.org/10.1055/s-0043-1768669)
297 0043-1768669
- 298 10. Jarius S, Aktas O, Azyzenberg I, Bellmann-Strobl J, Berthele A, Giglhuber K, et al. Update on the diagnosis and treatment
299 of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group

(NEMOS). Part I: Diagnosis and differential diagnosis. *Journal of Neurology* [Internet]. 2023 Apr 6;270(7):3341–68. Available from: <https://doi.org/10.1007/s00415-023-11634-0>

11. Karegal S., Bekele, N., Gebreweld Y., & Jadesse A. (2021). Neuroavititis Artica Spectrum Disorder: A Case Report. *International Medical Case Reports Journal*, Volume 14, 643-648

12. Bagherieh, S., Afshari-Safavi, A., Vaheb, S., Kiani, M., Ghaffary, E. M., Barzegar, M., Shaygannejad, V., Zabeti, A., & Mirmosayyeb, O. (2023). Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysis. *Neurological Sciences*, 44(6), 1905–1915.

13. Hamid, S. H. M., Whittam, D., Mutch, K., Linaker, S., Solomon, T., Das, K., Bhojak, M., & Jacob, A. (2017). What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. *Journal of Neurology*, 264(10), 2088–2094.

14. Wu, Y., Geraldes, R., Juryńczyk, M., & Palace, J. (2023). Double-negative neuromyelitis optica spectrum disorder. *Multiple Sclerosis Journal*, 29(11–12), 1353–1362.

15. Montcuquet, A., Collongues, N., Papeix, C., Zephir, H., Audoin, B., Laplaud, D., Bourre, B., Brochet, B., Camdessanche, J., Labauge, P., Moreau, T., Brassat, D., Stankoff, B., De Seze, J., Vukusic, S., & Marignier, R. (2016). Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. *Multiple Sclerosis Journal*, 23(10), 1377–1384.

16. Kojima, M., Oji, S., Tanaka, S., Izaki, S., Hashimoto, B., Fukaura, H., & Nomura, K. (2019). Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody. *Multiple Sclerosis and Related Disorders*, 39, 101907.

17. Ringelstein, M., Ayzenberg, I., Lindenblatt, G., Fischer, K., Gahlen, A., Novi, G., Hayward-Könnecke, H., Schippling, S., Rommer, P. S., Kornek, B., Zrzavy, T., Biotti, D., Ciron, J., Audoin, B., Berthele, A., Giglhuber, K., Zephir, H., Kümpfel, T., Berger, R., . . . Aktas, O. (2021). Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders. *Neurology Neuroimmunology & Neuroinflammation*, 9(1).